Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 04 - 30 crawled time : 00:20 save search
Concord Medical Files 2021 Annual Report on Form 20-F
Published: 2022-04-29 (Crawled : 00:20) - prnewswire.com
CCM | $0.5701 -1.69% 0.0% 0
|
Health Services
| Email alert
Add to watchlist
report
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BKKT, BKKT-WT, VIHAU, VIH, VIHAW
Published: 2022-04-29 (Crawled : 00:20) - prnewswire.com
EVBG | $34.89 -0.03% 0.0% 460
|
Technology Services
| Email alert
Add to watchlist
acquisition trial deadline
ATMOFIZER TECHNOLOGIES INC. ANNOUNCES YEAR END 2021 FINANCIAL RESULTS
Published: 2022-04-29 (Crawled : 00:20) - prnewswire.com
FNCTF | News | $11.16 1.13% 0
|
Communications
| Email alert
Add to watchlist
results
AGNICO EAGLE ANNOUNCES ELECTION OF DIRECTORS
Published: 2022-04-30 (Crawled : 00:20) - prnewswire.com
AEM | $63.69 1.22% 0.33% 2.6M
|
Non-Energy Minerals
| Email alert
Add to watchlist
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Published: 2022-04-29 (Crawled : 00:20) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
orgovyx treatment approval cancer prostate cancer
ST. JAMES GOLD CORP. ANNOUNCES APPOINTMENT OF DR. TSUN LAW TO ITS BOARD OF DIRECTORS & PRIVATE PLACEMENT FINANCING
Published: 2022-04-29 (Crawled : 00:20) - globenewswire.com
NFGC | News | $3.66 -3.68% 0.82% 190
|
| Email alert
Add to watchlist
Bilibili Provides Updates on Financial Guidance and Recent Business Developments
Published: 2022-04-30 (Crawled : 00:20) - globenewswire.com
BILI | $12.75 10.97% 9.92% 47K
|
Technology Services
| Email alert
Add to watchlist
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
Published: 2022-04-30 (Crawled : 00:20) - globenewswire.com
SUPN | $30.26 1.04% 1.02% 0
|
Health Technology
| Email alert
Add to watchlist
qelbree treatment fda adhd approval
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TRMK 4 | $29.89 1.81% 2.7K
|
Finance
TSHA | $2.375 1.06% 19K
|
Health Technology
TSN | $61.57 0.41% 14K
|
Consumer Non-Durables
TMUS S | $164.61 0.26% 190K
|
Communications
TTEC 4 | $8.02 1.5K
|
Commercial Services
TRMB S | $59.26 -0.42% 9.8K
|
Electronic Technology
AMED | $90.65 -0.44% 3.1K
|
Health Services
TRV | $211.8 -0.76% 21K
|
Finance
TRS 4 | $26.08 -0.76% 1K
|
Producer Manufacturing
TT | $294.15 -0.79% 21K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.